we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
Company profile
Ticker
CFRXQ, CFRX
Exchange
Website
CEO
Roger Pomerantz
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CFRXQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
27 Dec 23
8-K
Bankruptcy or Receivership
4 Dec 23
8-K
Cost Associated with Exit or Disposal Activities
15 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Nov 23
424B3
Prospectus supplement
3 Nov 23
EFFECT
Notice of effectiveness
3 Nov 23
CORRESP
Correspondence with SEC
31 Oct 23
S-1
IPO registration
30 Oct 23
UPLOAD
Letter from SEC
30 Oct 23
Latest ownership filings
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Michael Messinger
16 Feb 23
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 23
SC 13G/A
FEDERATED HERMES, INC.
9 Sep 22
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
19 Jul 22
4
Jane F Barlow
18 May 22
4
Cary Sucoff
18 May 22
4
MICHAEL J. OTTO
18 May 22
4
David N. Low
18 May 22
4
STEVEN C GILMAN
18 May 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.41 mm | 5.41 mm | 5.41 mm | 5.41 mm | 5.41 mm | 5.41 mm |
Cash burn (monthly) | 3.00 mm | (no burn) | 2.23 mm | 2.52 mm | 2.89 mm | 2.97 mm |
Cash used (since last report) | 19.91 mm | n/a | 14.76 mm | 16.70 mm | 19.16 mm | 19.67 mm |
Cash remaining | -14.50 mm | n/a | -9.35 mm | -11.28 mm | -13.75 mm | -14.25 mm |
Runway (months of cash) | -4.8 | n/a | -4.2 | -4.5 | -4.8 | -4.8 |
Institutional ownership, Q4 2023
13F holders | Current |
---|---|
Total holders | 203 |
Opened positions | 38 |
Closed positions | 110 |
Increased positions | 72 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 1.85 tn |
Total shares | 221.62 mm |
Total puts | 958.80 k |
Total calls | 1.49 mm |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
ARK Investment Management | 34.50 mm | $338.49 bn |
Vanguard | 26.79 mm | $262.81 bn |
Madrone Capital Partners | 16.42 mm | $0.00 |
CMTDF Sumitomo Mitsui Trust | 13.20 mm | $129.50 bn |
Nikko Asset Management Americas | 13.20 mm | $129.63 bn |
MS Morgan Stanley | 11.11 mm | $108.98 bn |
Jackson Square Partners | 9.70 mm | $95.20 bn |
Deep Track Capital | 7.00 mm | $68.67 bn |
Farallon Capital Management | 6.19 mm | $60.74 bn |
STT State Street | 5.62 mm | $55.17 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Feb 23 | Messinger Michael | Options Common Stock | Grant | Acquire A | No | No | 5.04 | 25,000 | 126.00 k | 25,000 |